Literature DB >> 1650790

Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus.

M A Rahman1, L A Kingsley, R W Atchison, S Belle, M C Breinig, M Ho, C R Rinaldo.   

Abstract

Reactivation of Epstein-Barr virus (EBV) in early human immunodeficiency virus (HIV) infection was investigated in 49 homosexual men who seroconverted to HIV (cases) as compared with 49 matched controls who remained seronegative to HIV during a longitudinal study. EBV infection was reactivated in cases 6 months, but not 12 months, prior to HIV seroconversion as compared with controls and remained reactivated during 18 months of follow-up after HIV seroconversion, as shown by increases in immunoglobulin (Ig) G antibody titers to EBV early antigen. Antibody titers to EBV viral capsid antigen did not differ between cases and controls prior to the time of seroconversion to HIV but were significantly increased among cases by the first seropositive study visit and remained elevated during the 18 months after HIV seroconversion. Total serum IgG levels were increased in cases at the visit of seroconversion, and during 18 months of follow-up, but did not correlate with enhanced IgG production specific for EBV antigens. Significant decreases in numbers of CD4+ cells and increases in numbers of CD8+ cells during this early phase of HIV infection were not associated with changes in patterns of EBV antibody responses. Reactivation of EBV beginning 6 months before HIV seroconversion may have implications regarding the role of this herpesvirus in the pathogenesis of HIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650790      PMCID: PMC269972          DOI: 10.1128/jcm.29.6.1215-1220.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Effects of human immunodeficiency virus (HIV) on the cytotoxic response to Epstein Barr virus (EBV) transformed B lymphocytes.

Authors:  R S Blumberg; T J Paradis; D Crawford; R E Byington; M S Hirsch; R T Schooley
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

Review 2.  Epstein-Barr virus: the spectrum of its manifestations in human beings.

Authors:  D T Purtilo
Journal:  South Med J       Date:  1987-08       Impact factor: 0.954

3.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  Increased Epstein-Barr virus DNA in oropharyngeal secretions from patients with AIDS, AIDS-related complex, or asymptomatic human immunodeficiency virus infections.

Authors:  G R Alsip; Y Ench; C V Sumaya; R N Boswell
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

5.  Evidence for disregulation in the control of Epstein-Barr virus latency in patients with AIDS-related complex.

Authors:  G Ragona; M C Sirianni; S Soddu; B Vercelli; G Sebastiani; M Piccoli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

6.  Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders.

Authors:  D L Birx; R R Redfield; G Tosato
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

7.  Association of HTLV-III with Epstein-Barr virus infection and abnormalities of T lymphocytes in homosexual men.

Authors:  C R Rinaldo; L A Kingsley; D W Lyter; B S Rabin; R W Atchison; A J Bodner; S H Weiss; W C Saxinger
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

8.  Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.

Authors:  R Yarchoan; R R Redfield; S Broder
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

9.  Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS.

Authors:  W A Andiman; R Eastman; K Martin; B Z Katz; A Rubinstein; J Pitt; S Pahwa; G Miller
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

10.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

View more
  11 in total

1.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.

Authors:  H Jenson; K McIntosh; J Pitt; S Husak; M Tan; Y Bryson; K Easley; W Shearer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study.

Authors:  Michiel B Haeseker; Evelien Pijpers; Nicole Htm Dukers-Muijrers; Patty Nelemans; Christian Jpa Hoebe; Cathrien A Bruggeman; Annelies Verbon; Valère J Goossens
Journal:  Immun Ageing       Date:  2013-07-23       Impact factor: 6.400

3.  Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy.

Authors:  Sidney Ogolla; Ibrahim I Daud; Amolo S Asito; Odada P Sumba; Collins Ouma; John Vulule; Jaap M Middeldorp; Arlene E Dent; Saurabh Mehta; Rosemary Rochford
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

4.  Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya.

Authors:  Erwan Piriou; Rhonda Kimmel; Kiprotich Chelimo; Jaap M Middeldorp; Peter Sumba Odada; Robert Ploutz-Snyder; Ann M Moormann; Rosemary Rochford
Journal:  J Med Virol       Date:  2009-06       Impact factor: 2.327

Review 5.  CD8 T cell persistence in treated HIV infection.

Authors:  Joseph C Mudd; Michael M Lederman
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

6.  Study of mother-to-child Epstein-Barr virus transmission by means of nested PCRs.

Authors:  M C Meyohas; V Maréchal; N Desire; J Bouillie; J Frottier; J C Nicolas
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 7.  Population levels of psychological stress, herpesvirus reactivation and HIV.

Authors:  Allison E Aiello; Amanda M Simanek; Sandro Galea
Journal:  AIDS Behav       Date:  2008-02-09

8.  Epstein-Barr virus infection in HIV-positive patients.

Authors:  A Telenti; D E Uehlinger; F Marchesi; D Germann; R Malinverni; L Matter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

9.  Holoendemic malaria exposure is associated with altered Epstein-Barr virus-specific CD8(+) T-cell differentiation.

Authors:  Pratip K Chattopadhyay; Kiprotich Chelimo; Paula B Embury; David H Mulama; Peter Odada Sumba; Emma Gostick; Kristin Ladell; Tess M Brodie; John Vulule; Mario Roederer; Ann M Moormann; David A Price
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 10.  Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1.

Authors:  Hideki Nakamura; Toshimasa Shimizu; Atsushi Kawakami
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.